Talon Private Wealth LLC Invests $631,000 in Neurocrine Biosciences, Inc. $NBIX

Talon Private Wealth LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 4,789 shares of the company’s stock, valued at approximately $631,000.

Several other institutional investors and hedge funds also recently made changes to their positions in NBIX. AQR Capital Management LLC increased its holdings in Neurocrine Biosciences by 18.0% in the fourth quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock worth $462,652,000 after purchasing an additional 498,058 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Neurocrine Biosciences by 8.0% during the 1st quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock worth $318,665,000 after buying an additional 180,100 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Neurocrine Biosciences by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock worth $291,342,000 after buying an additional 34,457 shares in the last quarter. Los Angeles Capital Management LLC grew its position in shares of Neurocrine Biosciences by 7.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock worth $178,248,000 after buying an additional 88,522 shares during the period. Finally, Northern Trust Corp grew its position in shares of Neurocrine Biosciences by 31.9% during the 4th quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock worth $173,201,000 after buying an additional 295,470 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Down 1.1%

NASDAQ NBIX opened at $180.79 on Thursday. The company has a market cap of $18.18 billion, a price-to-earnings ratio of 27.86, a P/E/G ratio of 0.77 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $183.50. The business has a 50 day moving average price of $167.01 and a 200-day moving average price of $145.90.

Insider Buying and Selling

In other Neurocrine Biosciences news, Director Stephen A. Sherwin sold 25,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the transaction, the director owned 15,860 shares in the company, valued at approximately $2,621,975.20. This represents a 61.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Charles Gorman sold 245,088 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total transaction of $37,824,431.04. Following the completion of the transaction, the director directly owned 511,293 shares in the company, valued at $78,907,848.69. This trade represents a 32.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 394,172 shares of company stock worth $62,221,181 over the last quarter. Corporate insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

NBIX has been the subject of several research analyst reports. Zacks Research upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Canaccord Genuity Group increased their target price on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Truist Financial raised their price target on shares of Neurocrine Biosciences from $155.00 to $200.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Piper Sandler lifted their price target on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Leerink Partners upped their price objective on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $194.05.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.